Pharma

Statistics in lines of code … so what?

Conducting a clinical study requires several steps and tools. Based on the scientific & biological question a promoter needs to address, he has to design the study, define the number of volunteers, recruit, monitor and collect data. Finally, once he gets the data,...

Medical device Regulation 2017/745: One more year!

Following our previous article on “New medical device Regulation 2017/745: Impact in nutrition field?”, it should have been time for the regulation to come into force. Indeed, the text should have been implemented on May 26, 2020, but due to the pandemic time, the...

[POSTER] Fecal microbiota profile at diagnosis in the French IMODI cohort of breast cancer

Oumaïra Rahmouni (1), Cindy Pensec (1), Steven Roblin (1), Yao Amouzou (1), Amandine Charreton (2), Patricia Lapierre (3), Séverine Tabone-Eglinger (2), Isabelle Treilleux (2), Olivier Tredan (2), Françoise Le Vacon (1), Sidonie N Lavergne (1) . (1) Biofortis Mérieux...

Human Microbiome Therapeutics – Interview of Kristin Wanneberger (Ferring Pharmaceuticals)

Several kinds of Human Microbiome Therapeutics (HMTs) are emerging as excellent candidates for innovative health strategies, but some scientific and regulatory challenges remain. Despite no current market authorization, Fecal Microbiota Transplantation (FMT),...
Statistics in lines of code … so what?

Statistics in lines of code … so what?

Conducting a clinical study requires several steps and tools. Based on the scientific & biological question a promoter needs to address, he has to design the study, define the number of volunteers, recruit, monitor and collect data. Finally, once he gets the data,...